Gas6 Induces Myelination through Anti-Inflammatory IL-10 and TGF-β Upregulation in White Matter and Glia.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
26 07 2020
Historique:
received: 24 06 2020
revised: 16 07 2020
accepted: 24 07 2020
entrez: 30 7 2020
pubmed: 30 7 2020
medline: 1 4 2021
Statut: epublish

Résumé

The Gas6-TAM (Tyro3, Axl, Mer) ligand-receptor system is believed to promote central nervous system (CNS) (re)myelination and glial cell development. An additional important function of Gas6-TAM signalling appears to be the regulation of immunity and inflammation, which remains to be fully elucidated in the CNS. Here, we characterised the expression of TAM receptors and ligands in individual CNS glial cell types, observing high expression of Gas6 and the TAM receptors, Mer and Axl, in microglia, and high expression of Tyro3 in astrocytes. We also investigated the effect of Gas6 on the inflammatory cytokine response in the optic nerve and in mixed glial cell cultures from wildtype and single TAM receptor knockout mice. In wildtype and Mer-deficient cultures, Gas6 significantly stimulated the expression of the anti-inflammatory/pro-repair cytokines interleukin 10 (IL-10) and transforming growth factor β (TGF-β), whereas this effect was absent in either Tyro3 or Axl knockout cultures. Furthermore, Gas6 caused upregulation of myelin basic protein (MBP) expression in optic nerves, which was blocked by a neutralising antibody against IL-10. In conclusion, our data show that microglia are both a major source of Gas6 as well as an effector of Gas6 action in the CNS through the upregulation of anti-inflammatory and pro-repair mediators. Furthermore, the presence of both Axl and Tyro3 receptors appears to be necessary for these effects of Gas6. In addition, IL-10, alongside suppressing inflammation and immunity, mediates the pro-myelinating mechanism of Gas6 action in the optic nerve. Therefore, Gas6 may present an attractive target for novel therapeutic interventions for demyelinating as well as neuroinflammatory disorders of the CNS.

Identifiants

pubmed: 32722558
pii: cells9081779
doi: 10.3390/cells9081779
pmc: PMC7465828
pii:
doi:

Substances chimiques

IL10 protein, human 0
Intercellular Signaling Peptides and Proteins 0
Transforming Growth Factor beta 0
growth arrest-specific protein 6 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Science. 2001 Jul 13;293(5528):306-11
pubmed: 11452127
J Neuroimmunol. 2005 May;162(1-2):71-80
pubmed: 15833361
Mol Cell Neurosci. 2005 Jul;29(3):381-93
pubmed: 15890528
Glia. 2014 Jun;62(6):881-95
pubmed: 24616125
J Neuroinflammation. 2013 Sep 22;10:117
pubmed: 24053338
Cell. 1995 Jan 27;80(2):213-23
pubmed: 7834741
J Immunol. 2012 Oct 1;189(7):3508-20
pubmed: 22942426
J Interferon Cytokine Res. 2014 Aug;34(8):615-22
pubmed: 25084178
Glia. 2011 Apr;59(4):540-53
pubmed: 21319221
J Exp Med. 1991 Nov 1;174(5):1209-20
pubmed: 1940799
PLoS One. 2011 Mar 10;6(3):e17727
pubmed: 21423702
PLoS One. 2012;7(5):e36800
pubmed: 22606290
J Pharm Pharmacol. 2020 Apr;72(4):539-550
pubmed: 32034779
J Immunol. 1991 May 15;146(10):3444-51
pubmed: 1827484
J Comp Neurol. 2000 Sep 18;425(2):295-314
pubmed: 10954847
ASN Neuro. 2016 Sep 14;8(5):
pubmed: 27630207
J Exp Med. 1994 Nov 1;180(5):1587-90
pubmed: 7964446
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
EMBO J. 2000 Jul 3;19(13):3159-67
pubmed: 10880430
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
J Neuroinflammation. 2012 Sep 04;9:210
pubmed: 22947253
Neuroscience. 1990;39(1):151-70
pubmed: 2089275
Nat Med. 2003 Jul;9(7):936-43
pubmed: 12796773
Cell Mol Life Sci. 2013 May;70(9):1663-72
pubmed: 23233134
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
J Immunol. 2013 Dec 15;191(12):6165-77
pubmed: 24244024
FEBS J. 2006 Dec;273(23):5231-44
pubmed: 17064312
Phytomedicine. 2017 Aug 15;32:8-14
pubmed: 28732811
J Neurosci. 2014 Dec 3;34(49):16320-35
pubmed: 25471571
Curr Opin Genet Dev. 1997 Aug;7(4):467-73
pubmed: 9309176
Curr Opin Immunol. 2003 Feb;15(1):31-6
pubmed: 12495730
J Immunol. 2005 Apr 1;174(7):4345-55
pubmed: 15778399
Nature. 1997 Dec 4;390(6659):465-71
pubmed: 9393997
Elife. 2019 May 09;8:
pubmed: 31071011
J Peripher Nerv Syst. 2011 Dec;16(4):334-40
pubmed: 22176148
J Neurosci. 2003 May 15;23(10):4208-18
pubmed: 12764109

Auteurs

Salman Goudarzi (S)

School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK.

Shannon E Gilchrist (SE)

School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK.

Sassan Hafizi (S)

School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH